Screener
Viking Therapeutics VKTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $118,116 | $165,810 |
| Short-term investments – available-for-sale | 484,848 | 539,929 |
| Prepaid clinical trial and preclinical study costs | 4,021 | 8,053 |
| Prepaid expenses and other current assets | 1,224 | 1,806 |
| Total current assets | 608,209 | 715,598 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's cash & equivalents?
- Viking Therapeutics (VKTX) reported cash & equivalents of $118.12M in Q1 2026.
- How has Viking Therapeutics's cash & equivalents changed year-over-year?
- Viking Therapeutics's cash & equivalents increased by 211.3% year-over-year, from $37.94M to $118.12M.
- What is the long-term trend for Viking Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Viking Therapeutics's cash & equivalents has grown at a 41.6% compound annual growth rate (CAGR), from $29.12M to $165.81M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Viking Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude